Duality Biotherapeutics, Inc. (HKG:9606)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
336.00
+9.00 (2.75%)
Feb 13, 2026, 4:08 PM HKT
Market Cap30.29B
Revenue (ttm)2.38B +8.7%
Net Income-3.10B
EPS-124.82
Shares Out90.14M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume402,131
Average Volume560,864
Open321.60
Previous Close327.00
Day's Range321.60 - 340.00
52-Week Range165.50 - 563.50
Betan/a
RSI52.15
Earnings DateApr 2, 2026

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 191
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9606
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements